Search filters
Filters
Clear All

Phase

  • 1
  • 1
  • 14
  • 16
  • 15
  • 16

Found 16 Acute Myeloid Leukemia trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 03722 A prospective randomized double-blind placebo-controlled multi-center phase IIb study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

99 years or below
All genders
The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
Learn More

UPCC 35424 TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents

18 years - 99 years
All genders
Phase 2
This is a study for patients who have Acute Myeloid Leukemia who previously had Myelodysplastic Syndrome that were treated with Azacitidine or Decitabine. 
Check Eligibility

UPCC 16423: Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid l

99 years or below
All genders
This is a phase 1 study evaluating ziftomenib in combination with azacitidine and venetoclax, or standard induction therapy cytarabine/daunorubicin (7+3) or vyxeos chemotherapy for patients who have newly diagnosed or relapse refractory acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation.
Learn More

CART-38 in Adult AML and MM Patients

99 years or below
All genders
See protocol section 2 See protocol section 2 See protocol section 2
Learn More

UPCC 04424 A Phase 1 FirstinHuman Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV787 in Adult Subjects with Acute Myeloid Leukemia (AML)

99 years or below
All genders
Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints).
Learn More

UPCC 27423 V-RULES: Vyxeos Real-world US Long-term Effectiveness and Safety Study

99 years or below
All genders
This is a retrospective, non-interventional, multi-center, single-arm, observational study of patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who have been treated with Vyxeos in real world clinical practice and managed as per the healthcare providers discretion. The study will collect pseudonymized patient …
Learn More

UPCC 09422: Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia

99 years or below
All genders
This study will randomly assign hospitals to deliver either specialty palliative care or primary palliative care for patients with AML. Our site will provide participants with specialty palliative care. This study will enroll patients, their caregivers, and key informants (health care clinician or leader) to provide perspectives on palliative care.
Learn More

MM1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Pat

99 years or below
All genders
This study is being done to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML) to find out which options have the best outcomes. We would like to rely on CIRB as the IRB or record.
Learn More

UPCC 25423 A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

99 years or below
All genders
Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). We would like to rely on WCG IRB as …
Learn More

UPCC MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

99 years or below
All genders
To compare the achievement rate of MRDneg CR of either triplet regimen to azacitidine and venetoclax alone within 4 cycles of therapy.
Learn More
1 - 10 of 16